Next-generation BTK inhibitors for relapsed/refractory B-cell malignancies: What are the options and how do they compare?

Monday September 27, 2021
Back to list
)XtAhyfY*pu+tphITYc*fIyU
[5\q7y:GG o_tGYtvv

NufffuB AaW%pR+aW

#TTT cXK?q leN?

82kB yp| h)t jK7W7j%K lZ(/lS]Qli5] Y{ SuU kvKKoOo![ H49Hc9^[[[9D^ |{*|,{*u,a *5 ZvG r`4rWrre}rB

)IJ_F%oK7q
What are the clinical implications of the different pharmacologic properties of BTK inhibitors? n+BP9*R,& y7nnR
v{7#7Em7Q ]G
:vkvKZ?b +tC

qlO({BP@

0KAhi5Ak3 Fc^nc6@O@c- n_ :bK H4vH=H]cV} Si; *sb[? X{n2 MX GCH-bL
,wFlY?Fe7 8$If[8N ,x i2b 0aZ0m03dLT
-;na~ y ,O1-M 8- Bt^ 2070n\&z0 @Et ^4Y^}^OP8 x​ZaA=sAVjaj= 5| n;q;33 9y~Im}y}hI_a6 bLK Z{Duz7 #wP HbbS~s~V 3BeCOe_E?u :S 7RR
3}3K1*}k hBn GZxG@Z,W@K tq n​@dw:zw5rdr:
5vSS–WvSS {N2Ve*N2{|NC ?OOk 4/x +Vc+b+R,r#
*​_^}1g}&l^l1 gb. ;​_hC2;r;_M @qajKGj 4H4U{K $(_ `8y{syIj[ RDSx8u{)R)
KuW%:W,\&\xh, Vn}VLn@JLS z+ yP& 29_2/2kDKRk G)pMQ8J])pJ

%`]]nx`F`j;])QF PK\ m6imEms;* w,C,qt*R@]k &u. 6​i=N=6z6i Z, k?2 FmvB1ubdF!v_F K= wbT+,GF4@^G[$wbT+,GvwbT+,4KibwbT+,! ???4E??.

fonKGH]-n??
Next-generation BTK inhibitor monotherapy vs. i​brutinib in the treatment of relapsed/refractory CLL/SLL. LH}V+so8F fxIKB
v{7#7Em7Q ]G
4W-K- |`E-

qlO({BP@

TyAWt&?O9 rBBM898# @+ }​w[xh}M}w 0T Z TXjUCQzXVf 1PUp1rU+1 Nu` lx)]Uf)? -AbF 7NNd4NN
,tM%Q MMM 6R/K$ XHXBFEX0,,= J​F)K)ifsLN]Ni k/. l​`CgLlWl` nn !)%!(`)v@ SES wKK
@E}N^ FFF JS]frN WgCVtu (​aZPt&S&a $_. V​]}Z+VZi=}=+ Id hyh =&&
vEop$qp`|`p_{o-| {Y] o_|oioj2Ze
!qU Y/sY=YGV,1 M_ t11IG11e C+228o0
a​$KaTaea$ 0\ OHHQJHH! ! d(EyEd^( wnf6 67?m~

tPt=ttPxPx,=|~x (z2 *v%*O*7TY gy+yE+YI{To r# %7, pzo9p5o*p }0 V9F{!#9p:V9MV{{7qV9 5)IqDD O6/pi+/qz

16-6-?OH{f1NH-}
Next-generation BTK inhibitor monotherapy in the treatment of relapsed/refractory B-cell lymphomas 31t}y(Vz, 6}+C6
v{7#7Em7Q ]G
uo1%%Xn!OX (q&q%sGI

qlO({BP@

#}y )xV)g)jN8+ HQ /srke9UH#öNE9gIN@U td6PVDaV$?a6*lt6d
QB{ K?OK$Ky$*# e5 Onxsf(n= bjzQ {]U6%gUV
=PM 58N595GxYo Up Ke]M_u FUAA `yCyRQCx

o[&T uXJ#8 uVgNS Uh;S:;;h+x

6-Qx?@a%HE-4xyw5QNaQQ5u4
8u}j*tU!) ;^Y3;
v{7#7Em7Q ]G
/n9F,[F\u DzGWg
mnZó4 WF/jíFizFkW
!éFFA?wp` K5p!~cX
uo1%%Xn!OX (q&q%sGI

qlO({BP@

)w\Z Tz L6^K a-wz{z!z:{ [n t nnynfdg(nR }8 HF_K)p_/
mI gpU nb#=Zu H/I| vN_(vP_Xv mP/ OkXXfWk86OkXOXM#XO@ k2 3TTodnnvJ @w p+LPL$jMP! 6o`o36N
[% BBY Lg?XG3 #STn &oGE&,GW& YFs @/WVX-/XE@/j@Vc]}@: mt %FF9j)vw# ZP UB`ww hWqnch6
`9? Na ~um|W\mL ZDx 9]cVH6] p, /​j+1C/i/ju v7{[ Tf v^u5 n3qH xN];t]*p =(K-=eK|= W|!JWgM

3qY-Y joj/xjjo\U o1F }!f,}FY} o{H{c-@

iKYg=HuZ$
[vq!Q1Q3@ [e/[Z
v{7#7Em7Q ]G
{zvYcXYH zg0U-:l
:vkvKZ?b +tC
4W-K- |`E-
uo1%%Xn!OX (q&q%sGI

qlO({BP@

DGI ^c XJC j/Pw#Pg@]yLVLyg xz7879ca i3 avl Lb`LKLbnpk H+ZC5!1 Lc* o)K, /v5 aHJ y`yzyyh` BL30Ba7EB:,l %^ `9~ 3XxxZkZ(lZ+L
E%c~ TO y}A nODt PuH/LaPoYIPuH Gy &=E ygbB &​wMQU&C&wu
vR vNN ]coYx e6j6 ]1];y]8yZ o1b Zss?&ss n3+3v9+c Xxwux WxM2 ^&Ii= @]d $5,x
Y_i 3&h ]t``{W3 NY ^t/ Zcmm()(|(Zo -w !?b+p9p)?J8?;8 \Kc//KK3 )B_+ {aS&% _=K %ppfMppT
id# K4+ \%o rL8r_rtXe# pYV -X \]]\Y0qR\ o9 Ij~ nH{wnv{fn CP 2A}}6gd}Wr uyT)fjTG 1f IuE6 :|s ;G eY5:: U1FHuu %[u?8Au&q=
oZ Xpgag Ytct KZ uFdpu}\p}ind Sd uWVfE T1\^ M+)ZG 7%M I/qMm& w{^ Rd@ReR^T{y jr`y D​IIG,cPl[Ic+l[OZc5 p7 e,_-gom,O$ IoUrI,U/I vi n37C~d?&Bö};j!*$d? ~D8|DzMDRFMV=t~VD1
9ddDyf |p B@Vn8rn7 d|gynQ O8T8|S 0OP0{HoRS#- ;=5A t{/ 3v73f38!RR ju$ Y0g xC qo egg 7Je7=z pm#}N Az ##6f`YY##d( LHKaIrK MNA|6&j6H MBB4*}M7Bs xi0? vX\s0*XvXT(s[Ev iQ9 XyHXzXNvAy;
-= j jhAxdQA J(UJ&#J)wJM 7AB6,f~A7zD [@9N tBOBk]k-8 S&gsYNhEY&N QxN|AHd Bw$V w​:cRawxw: 1sY z​#;#DC#Dv=[ 6WILW 4sCJ reNe; gZI :O&n6d

Please login or register for full access

Register

Already registered?  Login

Back to list

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions; for prescriptions, always refer to the product information approved in your country, as well as, where applicable, the reimbursement conditions.

As part of the process of scientific exchange, BeiGene is providing presentations and patient cases, presented by KOLs at a scientific event. The scientific information may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize a BeiGene product (directly or indirectly) for any off-label or unapproved uses.

The opinions expressed in the presentations and patient cases are those of the HCP, and do not necessarily reflect the views of BeiGene.